Aro Biotherapeutics
PA - PhiladelphiaBiotechnology
Focus: Aro Biotherapeutics is a public biotechnology company headquartered in Philadelphia focused on protein scaffold and antisense oligonucleotide technologies for gene therapy applications. The company is in early-stage development with a single Phase 1 program.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Aro Biotherapeutics?
AI assessmentHigh-risk early-stage bet suitable only for scientists/engineers seeking platform exposure with limited job security or near-term career advancement.
Why Work Here
- Early-stage gene therapy platform with proprietary protein scaffold and antisense technology offering ground-floor opportunity to shape emerging modalities
- Public company status provides liquidity and potential upside participation versus private equity
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ABX1100
Late Onset Pompe DiseaseClinical Trials (1)
NCT06109948Study to Assess the Safety, Tolerability, PK and PD of ABX1100
Phase 1Help build intelligence for Aro Biotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.